

Bobo Petrushev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11822607/publications.pdf>

Version: 2024-02-01

44
papers

620
citations

623734

14
h-index

677142

22
g-index

45
all docs

45
docs citations

45
times ranked

953
citing authors

#	ARTICLE	IF	CITATIONS
1	SERS-based DNA methylation profiling allows the differential diagnosis of malignant lymphadenopathy. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2022, 264, 120216.	3.9	11
2	Mechanistic Insights in Hemophagocytic Lymphohistiocytosis: Subsequent Acute Hepatic Failure in a Multiple Myeloma Patient Following Therapy with Ixazomib-Lenalidomide-Dexamethasone. <i>Journal of Personalized Medicine</i> , 2022, 12, 678.	2.5	1
3	A narrative review of central nervous system involvement in acute leukemias. <i>Annals of Translational Medicine</i> , 2021, 9, 68-68.	1.7	25
4	Correlation between the prevalence of T-cell lymphomas and alcohol consumption. <i>Medicine and Pharmacy Reports</i> , 2021, 94, 298-306.	0.4	0
5	Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 4483.	2.4	4
6	Extramedullary Hematopoiesis of the Liver and Spleen. <i>Journal of Clinical Medicine</i> , 2021, 10, 5831.	2.4	19
7	Transforming growth factor β -mediated micromechanics modulates disease progression in primary myelofibrosis. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 11100-11110.	3.6	11
8	Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP. <i>Diagnostics</i> , 2020, 10, 629.	2.6	0
9	B Cells versus T Cells in the Tumor Microenvironment of Malignant Lymphomas. Are the Lymphocytes Playing the Roles of Muhammad Ali versus George Foreman in Zaire 1974?. <i>Journal of Clinical Medicine</i> , 2020, 9, 3412.	2.4	2
10	The Influence of Methylating Mutations on Acute Myeloid Leukemia: Preliminary Analysis on 56 Patients. <i>Diagnostics</i> , 2020, 10, 263.	2.6	3
11	Day 15 and Day 33 Minimal Residual Disease Assessment for Acute Lymphoblastic Leukemia Patients Treated According to the BFM ALL IC 2009 Protocol: Single-Center Experience of 133 Cases. <i>Frontiers in Oncology</i> , 2020, 10, 923.	2.8	12
12	SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?. <i>Frontiers in Oncology</i> , 2020, 10, 1024.	2.8	3
13	Differential Diagnosis of Malignant Lymphadenopathy Using Flow Cytometry on Fine Needle Aspirate: Report on 269 Cases. <i>Journal of Clinical Medicine</i> , 2020, 9, 283.	2.4	5
14	Exosome-Carried microRNA-375 Inhibits Cell Progression and Dissemination via Bcl-2 Blocking in Colon Cancer. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 435-443.	0.9	76
15	MicroRNA-155-5p Plays a Critical Role in Transient Leukemia of Down Syndrome by Targeting Tumor Necrosis Factor Receptor Superfamily Members. <i>Cellular Physiology and Biochemistry</i> , 2020, 54, 994-1012.	1.6	4
16	Approach to the Adult Acute Lymphoblastic Leukemia Patient. <i>Journal of Clinical Medicine</i> , 2019, 8, 1175.	2.4	28
17	Persistent Basophilia May Suggest an "Accelerated Phase" in the Evolution of CALR-Positive Primary Myelofibrosis Toward Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 872.	2.8	12
18	Transient leukemia of Down syndrome. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019, 56, 247-259.	6.1	8

#	ARTICLE	IF	CITATIONS
19	Letâ€™s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Immunology</i> , 2019, 10, 2856.	4.8	8
20	Paraneoplastic hypereosinophilia in a patient with peripheral T cell lymphoma, not otherwise specified. <i>Medicine and Pharmacy Reports</i> , 2019, 92, 421-426.	0.4	3
21	Next-generation sequencing-based characterization of the invasion by anatomical contiguity in a primary osseous diffuse large B-cell lymphoma. Correlation between the genetic profile of the malignancy and the clinical outcome of the patient. <i>Histology and Histopathology</i> , 2019, 34, 663-670.	0.7	5
22	Cutaneous wound healing using polymeric surgical dressings based on chitosan, sodium hyaluronate and resveratrol. A preclinical experimental study. <i>Colloids and Surfaces B: Biointerfaces</i> , 2018, 163, 155-166.	5.0	35
23	Hodgkinâ€™s lymphoma and its association with EBV and HIV infection. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 102-114.	6.1	22
24	Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis. <i>Journal of Cellular Physiology</i> , 2018, 233, 422-433.	4.1	9
25	Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 501-515.	6.1	27
26	Genetically enhanced T lymphocytes and the intensive care unit. <i>Oncotarget</i> , 2018, 9, 16557-16572.	1.8	5
27	The role of the pathology department in the preanalytical phase of molecular analyses. <i>Cancer Management and Research</i> , 2018, Volume 10, 745-753.	1.9	12
28	Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 329-345.	6.1	14
29	Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Immunology</i> , 2018, 9, 239.	4.8	35
30	Oral manifestations in stem cell transplantation for acute myeloid leukemia. <i>Medical Hypotheses</i> , 2018, 121, 191-194.	1.5	9
31	Protein dysregulation in graft versus host disease. <i>Oncotarget</i> , 2018, 9, 1483-1491.	1.8	9
32	Ruxolitinib-conjugated gold nanoparticles for topical administration: An alternative for treating alopecia?. <i>Medical Hypotheses</i> , 2017, 109, 42-45.	1.5	13
33	In vivo assessment of bone marrow toxicity by gold nanoparticle-based bioconjugates in Crl:CD1(ICR) mice. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 4261-4273.	6.7	12
34	Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy. <i>International Journal of Nanomedicine</i> , 2016, 11, 641.	6.7	34
35	Knocking down of p53 triggers apoptosis and autophagy, concomitantly with inhibition of migration on SSC-4 oral squamous carcinoma cells. <i>Molecular and Cellular Biochemistry</i> , 2016, 419, 75-82.	3.1	22
36	Clinicopathological analysis of a case series of peripheral T-cell lymphomas, not otherwise specified, of lymphoepithelioid variant (Lennert's lymphoma). A Central European single-center study. <i>Human Pathology</i> , 2016, 53, 192-194.	2.0	9

#	ARTICLE	IF	CITATIONS
37	Chronic granulomatous dermatosis as a presenting sign of cutaneous T-cell lymphomas. <i>European Journal of Dermatology</i> , 2015, 25, 210-210.	0.6	3
38	Bicytopenia as a paraneoplastic syndrome for pseudomyxoma peritonei. Hematologic manifestations of a subtle disease. <i>International Journal of General Medicine</i> , 2015, 8, 93.	1.8	0
39	MicroRNAs as biomarkers for graft-versus-host disease following allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 1081-1092.	1.8	22
40	BCR-ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice. <i>Leukemia and Lymphoma</i> , 2015, 56, 546-547.	1.3	7
41	The role of microRNAs in the pathogenesis of HIV-related lymphomas. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2015, 52, 232-241.	6.1	15
42	Magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab. <i>Cancer</i> , 2014, 120, 4005-4006.	4.1	6
43	Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2012, 21, 187-96.	0.9	40
44	Arsenic trioxide plus cisplatin/interferon β /doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2011, 4, 60-66.	0.9	19